More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$29.62B
EPS
2.54
P/E ratio
33.3
Price to sales
6.39
Dividend yield
--
Beta
1.454458
Previous close
$84.46
Today's open
$82.73
Day's range
$79.20 - $82.85
52 week range
$54.11 - $92.59
show more
CEO
Jacob S. Leach
Employees
11100
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
372950922
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
DexCom to Launch 15-Day G7 CGM System in Canada This November
DXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.
Zacks Investment Research • Nov 3, 2026

Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platform for people around the world to put into words everything they've wanted to say about their diabetes journey, from the heartfelt and humorous to the hopeful and unexpected.Throughout November, anyone touched by diabetes is invited to share their own letter to diabetes, includi.
Business Wire • Nov 2, 2026

DexCom: Improving Patient Access Makes It A Long-Term Buy
DXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that expanded opportunity. Also, DXCM now offers longer-wear sensors, and they intend to increase their manufacturing scale. So, those factors combined could improve margins as well.
Seeking Alpha • Nov 2, 2026

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
Zacks Investment Research • Oct 30, 2026

Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide
Diabetes wearables-maker Dexcom topped third-quarter earnings forecasts Thursday and reported in-line sales. Dexcom stock was little moved.
Investors Business Daily • Oct 29, 2026

What DexCom (DXCM) Said on Its Q3 Earnings Call
DexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported higher profitability.
MarketBeat • Oct 29, 2026

DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 30, 2026

Dexcom Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.
Business Wire • Oct 29, 2026

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.
Zacks Investment Research • Oct 29, 2026

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and.
Business Wire • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell DexCom Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.